Model-based sensitivity analysis for outcome reporting bias in the meta analysis of benefit and harm outcomes

Statistical Methods in Medical Research

Volumn 28, Issue 3, 2019, Pages 889-903

  Copas, John ^a   Marson, Anthony ^b   Williamson, Paula ^b   Kirkham, Jamie ^b  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

meta analysis; Outcome reporting bias; Outcome Reporting Bias in Trials classification; selective reporting

Indexed keywords

TOPIRAMATE; ANTICONVULSIVE AGENT;

ABNORMAL THINKING; ADD ON THERAPY; ARTICLE; ATAXIA; BODY WEIGHT LOSS; COCHRANE LIBRARY; DIZZINESS; DRUG RESISTANT EPILEPSY; DRUG WITHDRAWAL; FATIGUE; FOCAL EPILEPSY; HEADACHE; HUMAN; MANTEL HAENSZEL TEST; MAXIMUM LIKELIHOOD METHOD; MENTAL CONCENTRATION; META ANALYSIS (TOPIC); NAUSEA AND VOMITING; OUTCOME REPORTING BIAS; PARESTHESIA; SENSITIVITY ANALYSIS; SIDE EFFECT; SIMULATION; SOMNOLENCE; SPEECH DISORDER; ALGORITHM; METHODOLOGY; STATISTICAL BIAS; STATISTICAL MODEL;

ALGORITHMS; ANTICONVULSANTS; BIAS; DRUG RESISTANT EPILEPSY; EPILEPSIES, PARTIAL; HUMANS; META-ANALYSIS AS TOPIC; MODELS, STATISTICAL; OUTCOME ASSESSMENT, HEALTH CARE; RESEARCH DESIGN; SYSTEMATIC REVIEWS AS TOPIC; TOPIRAMATE;

EID: 85045221335     PISSN: 09622802     EISSN: 14770334     Source Type: Journal    
DOI: 10.1177/0962280217738546     Document Type: Article

References (27)

1. Alderson P, Tan T. Use of Cochrane Reviews in NICE clinical guidelines [editorial]. Cochrane Database Syst Rev 2011; 12: ED000032–ED000032.
2. Hutton JL, Williamson PR. Bias in meta-analysis due to outcome variable selection within studies. Appl Stat 2000; 49: 359–370.
3. Dwan K, Gamble C, Williamson PR, Systematic review of the empirical evidence of study publication bias and outcome reporting bias - An updated review. PLoS One 2013; 8: e66844–e66844.
4. Saini P, Loke YK, Gamble C, Selective reporting bias of harm outcomes within studies: findings from a cohort of systematic reviews. Br Med J 2014; 349: g6501–g6501.
5. Kirkham JJ, Dwan K, Dodd S, The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. Br Med J 2010; 340: c365–c365.
6. Copas JB, Dwan K, Kirkham JJ, A model-based correction for outcome reporting bias in meta-analysis. Biostatistics 2014; 15: 370–383.
7. Pulman J, Jette N, Dykeman J, Topiramate add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev 2014, Issue 2. Art. No.: CD001417. DOI: 10.1002/14651858.CD001417.pub3.
8. Ben-Menachem E, Henriksen O, Dam M, et al. Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia 1996; 37: 539–543
9. Elterman RD, Glauser TA, Wyllie E, et al. A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children. Neurology 1999; 52: 1338–1344
10. Faught E, Wilder BJ, Ramsay RE, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Neurology 1996; 46: 1684–1690.
11. Guberman A, Neto W and Gassmann-Mayer C. EPAJ-119 Study Group. Low-dose topiramate in adults with treatment-resistant partial-onset seizures. Acta Neurologica Scandinavica 2002; 106: 183–189
12. Korean Topiramate Study Group. Topiramate in medically intractable partial epilepsies: double-blind placebo-controlled randomized parallel group trial. Epilepsia 1999; 40: 1767–1774
13. Privitera M, Fincham R, Pnery J, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages. Neurology 1996;46: 1678–1683.
14. Rosenfeld W, Abou-Khalil B, Reife R, et al. Topiramate YF/YG Study Group. Placebo-controlled trial of topiramate as adjunctive therapy to carbamazepine or phenytoin for partial-onset seizures. Epilepsia 1996; 37(Suppl 5): 153.
15. Sharief M, Viteri C, Ben-Menachem E, et al. Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy. Epilepsy Research 1996; 25: 217–224
16. Tassinari CA, Michelucci R, Chauvel P, et al. Double-blind, placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy. Epilepsia 1996; 37: 763–768
17. Yen DJ, Yu HY, Guo YC, et al. A double-blind, placebo-controlled study of topiramate in adult patients with refractory partial epilepsy. Epilepsia 2000; 41: 1162–1166
18. Zhang L, Huang J, Zhuang JH, et al. Topiramate as an adjunctive treatment for refractory partial epilepsy in the elderly. Journal of International Medical Research 2011; 39: 408–415
19. Coles H, Baker G and O'Donoghue M. Seizure severity in patients with partial onset (POS) or primary generalised tonic-clonic (PGTC) seizures following treatment with topiramate. A comparison of two different methodologies in a randomised controlled trial. Epilepsia 1999; 40(Suppl 2): 285
20. Higgins JPT, Deeks JJ and Altman DG (eds). Chapter 16: Special topics in statistics. In: Higgins JPT and Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
21. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719–748.
22. Hardy RJ, Thompson SG. A likelihood approach to meta-analysis with random effects. Stat Med 1996; 15: 619–629.
23. Williamson PR, Gamble C. Application and investigation of a bound for outcome reporting bias. Trials 2007; 8: 9. DOI:10.1186/1745-6215-8-9
24. Kirkham JJ, Riley RD, Williamson PR. A multivariate meta-analysis solution for reducing the impact of outcome reporting bias in systematic reviews. Stat Med 2012; 31: 2179–2195.
25. Chan AW, Krleza-Jeric K, Schmid I, Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research. Can Med J 2004; 171: 735–740.
26. Little RJA, Rubin DB. Statistical analysis with missing data, 2nd ed. New York: Wiley, 2002.
27. Rubin DB. Inference and missing data. Biometrika 1976; 63: 581–592.